The latest research news in genetics and genomics.
The firm will use the proceeds to continue developing its Proteograph platform, build its proteomic database, and develop liquid biopsy products for early disease detection.
The UK company plans to launch a CE-IVD version of the test in 2021 and anticipates launch of an FDA-cleared test shortly thereafter.
The test uses turbidimetry to measure levels of fecal calprotectin, a neutrophilic protein biomarker of intestinal mucosal inflammation.
Quanterix said that the acquisition will secure the supply of neurofilament light antibodies that are critical to its Simoa assays and services.
The new grant will be used to conduct whole-exome sequencing on 1,000 children participating in an autism spectrum disorder study for the purposes of biomarker development.
